New Study (April 2026): GLP-1 Weight Loss Exercise Is the Missing Piece Most Users Ignore
A study published just days ago by Omada Health found that GLP-1 users who combined structured exercise with their medication lost 1.8 times more total weight and reduced body fat percentage twice as much compared to a control group.
Omada members in its GLP-1 Care Track also saw an increase in muscle mass percentage and improvements in other well-being measures. That is a game-changing finding — and most people on Wegovy or Zepbound are not acting on it.
Why This Matters in 2026
The number of Americans on incretin-based therapies, such as GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists, has increased by 587% in the last five years. Millions are losing weight — but the composition of that weight loss is where things get complicated.
Long-term weight maintenance is more successful when exercise is included, as stopping GLP-1 therapy alone often leads to weight regain, while exercise helps preserve muscle mass and sustain weight loss. The drug is the catalyst; movement is the engine that keeps results permanent.
Key takeaway: GLP-1 weight loss exercise is not optional in 2026 — it is the factor that separates short-term results from lasting body transformation.
What Combining GLP-1 Medications With Exercise Actually Does to Your Body
Recent literature shows that GLP-1 receptor agonists are highly effective for weight loss and improving metabolic and cardiovascular health, often surpassing the results of lifestyle interventions alone, such as exercise and diet modification. But the drug alone has a critical vulnerability: lean mass loss.
Here is what the science now tells us about the combined approach:
- 25–40% of weight lost on GLP-1 receptor agonists typically comes from lean mass, according to a meta-analysis in *Obesity Reviews* — making muscle preservation a top clinical priority.
- Combining GLP-1 receptor agonists with structured lifestyle changes, especially increased protein intake and strength training, can mitigate muscle loss and enhance overall outcomes.
- Exercise helps preserve muscle mass and sustain weight loss, and long-term weight maintenance is significantly more successful when exercise is a consistent part of the regimen.
Key takeaway: GLP-1 weight loss exercise works synergistically — the medication burns fat while targeted movement ensures that what you keep is strong, functional muscle.
The Data: What Recent Research Actually Shows
Clinical studies using DEXA show that GLP-1-based weight loss is accompanied by some loss of lean mass, but fat loss predominates. In the landmark STEP-1 semaglutide trial, lean mass decreased by approximately 9.7% while fat mass fell by approximately 19.3%, with the proportion of lean mass actually increasing by about three percentage points.
That ratio improves dramatically with exercise. In a published case series of patients who exercised four to seven days per week while on GLP-1 therapy, one patient lost 33% of body weight with a fat mass reduction of 53.4% and a lean soft tissue loss of only 6.9% — another actually gained 2.5% lean soft tissue.
In the SEMALEAN study of 115 patients on semaglutide 2.4 mg, mean weight loss reached 13% by 12 months, total fat mass decreased by 18%, and lean mass initially declined but then stabilised — while handgrip strength actually improved by 4.5 kg at 12 months.
A 2026 secondary analysis published in *Sports Medicine* examined the efficacy of exercise and GLP-1 receptor agonist treatment alone or combined on physical fitness in adults with obesity, further confirming that the combination outperforms either approach in isolation.
Key takeaway: The data is unambiguous — pairing structured exercise with GLP-1 therapy dramatically shifts weight loss toward fat, not muscle.
How to Structure Your GLP-1 Weight Loss Exercise Routine
This is the exact protocol supported by current evidence. Follow each step in order.
- Step 1: Start resistance training 2–3 times per week. Research and clinical experience show that muscle loss can be significantly reduced by resistance training two to three times per week combined with adequate protein intake. Prioritize compound lifts — squats, deadlifts, rows, and presses.
- Step 2: Add moderate cardio on separate days. Aim for 30 minutes of moderate- to high-intensity exercise, four to five days per week to maximize cardiovascular adaptation and fat oxidation without overtaxing recovery.
- Step 3: Hit your daily protein target. Collaborate with a registered dietitian or track independently to maintain adequate protein intake — generally 1.2 to 2.0 grams per kilogram of body weight, depending on training status and goals.
- Step 4: Build in behavioral support. Structured exercise programs foster intrinsic motivation, self-regulation, and a positive relationship with the body, promoting sustained engagement even after pharmacotherapy discontinuation.
- Step 5: Track body composition, not just scale weight. Percent body fat reduction — not just overall weight loss — is closely linked to lowering the risk of metabolic disease. Loss of lean mass carries risks including reduced physical function, worse long-term musculoskeletal health, and a slower metabolism.
Key takeaway: A structured, weekly rhythm of strength training, cardio, and high protein is the only proven way to make GLP-1 weight loss exercise results stick for the long term.
Mistakes to Avoid on GLP-1 Medications and Exercise
- Mistake 1: Skipping strength training entirely. Cardio alone will not protect muscle. The Physical Activity Working Group of the European Association for the Study of Obesity has highlighted that resistance training — rather than aerobic exercise — specifically attenuates lean body mass loss during weight-loss interventions in adults with overweight or obesity.
- Mistake 2: Relying on the drug alone without lifestyle change. In a 2021 randomized clinical trial published in *JAMA*, participants who stopped semaglutide regained roughly two-thirds of their prior weight loss within a year — a stark reminder that medication without habits is a temporary fix.
- Mistake 3: Ignoring appetite suppression when it affects protein intake. GLP-1 users may experience reduced energy intake overall, making recovery nutrition and protein timing more crucial than ever — not less. Eating less is good; eating too little protein is not.
Frequently Asked Questions
Q: Can you build muscle while taking semaglutide or tirzepatide?
A: Case series data demonstrates the potential for minimal lean soft tissue loss, or even increases in lean soft tissue, during treatment with semaglutide and tirzepatide. Consistent exercise participation and resistance training are hypothesized to have contributed to the favorable body composition outcomes observed.
Q: What happens to your weight loss if you stop exercising while on a GLP-1?
A: Stopping GLP-1 therapy alone often leads to weight regain, while exercise helps preserve muscle mass and sustain weight loss — meaning exercise is the long-term anchor for any results achieved during treatment. Future obesity management is likely to prioritize integrated approaches that combine pharmacotherapy with lifestyle interventions, rather than replacing lifestyle changes with medication alone.